Randomized Controlled Trial of ADAPT
Condition(s) studied
Investigational drug(s) / intervention(s)
ADAPT: The ADAPT intervention consists of three group sessions (of 75-90 min), with 6-8 8th grade students in each group, administered over three consecutive weeks, plus one interactive parent component (of 45 min) administered during the three weeks (separate from the student sessions).
Study summary
This trial examines the effectiveness of a novel neurodevelopmentally informed intervention - Adolescent Developmentally-Appropriate health Promotion Therapy (ADAPT) - on preventing alcohol use and promoting well-being among students in middle school in a heavy adolescent alcohol use region (Denmark). Using a 2-condition cluster-randomized controlled trial of students in 8th grade (ages 13-15), the following hypotheses are tested:
1. Compared to adolescents in the Delayed Treatment Condition (DTC), ADAPT adolescents will show significant reductions in intentions to drink (primary outcome) from baseline to 3 months post intervention.
2. Compared to adolescents in the DTC, ADAPT adolescents will show significant reductions in alcohol use and alcohol-related consequences, and significant increases in well-being and life satisfaction (secondary outcomes) from baseline to 3 months.
Additionally, acceptability and feasibility is examined.
Eligibility
Primary outcome measure(s)
- Intentions to drink — From baseline to 3 months post intervention
Assessed by single items assessing intention to drink at least one unit of alcohol and intention to get drunk (dichotomized).
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Centre for Alcohol and Drug Research, Department of Psychology and Behavioral Sciences, Aarhus BSS, Aarhus University, Aarhus, Denmark | Aarhus | Denmark |
More University of Aarhus trials in Denmark
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07132866 on ClinicalTrials.gov ↗ ← All trials in Denmark